Arzerra is currently not available.
Our suppliers are constantly updating their product inventory and availability status. If you would like us to notify you when Arzerra becomes available, please fill out the form below.
*We value your privacy! We will never give, lease, sell or otherwise disclose your personal information. Period!
Browse Alphabetically:
A · B · C · D · E · F · G · H · I · J · K · L · M · N
O · P · Q · R · S · T · U · V · W · X · Y · Z · #
Information about ExpressMedsCanada.com
List of countries where we can ship Arzerra:
Latest news releases on Arzerra:
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer. Founded in 1999, the company's first marketed antibody, ofatumumab ...
Dissemination of a Adhoc News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. - Milestone payment of DKK 20 million triggered in connection with Japanese New Drug Application filing ...
Arzerra(r) net sales increased 32% over Q1 2011 New Drug Application for ofatumumab submitted in Japan Amended protocol for ofatumumab Phase III head to head study vs rituximab in DLBCL; moved estimated primary data readout forward Improved ...
increase was mainly driven by higher Arzerra(r) royalties and the inclusion of one milestone under our collaboration with Lundbeck. -- Operating expenses decreased 5% from DKK 145 million in the first quarter of 2011 to DKK 138 million in the first quarter of 2012.
approved therapeutic agents including the small-molecule drugs bendamustine (Ribomustin(®)) and fludarabine (Fludara(®)) as well as the anti-CD20 antibodies rituximab (Rituxan(®)) and ofatumumab (Arzerra(®)) were evaluated for their ability to enhance ...
In the lawsuit, started in October 2009, GSK had sought a declaration that the Cabilly II / III patents were invalid, unenforceable and not infringed by the manufacture, use, sale, offer to sell or importation of GSK's ofatumumab (ARZERRA) antibody product.
approved therapeutic agents including the small-molecule drugs bendamustine (Ribomustin(®)) and fludarabine (Fludara(®)) as well as the anti-CD20 antibodies rituximab (Rituxan(®)) and ofatumumab (Arzerra(®)) were evaluated for their ability to enhance ...
(Abstract No. 6507.) Abstract No. 6508 reports on interim results from a phase Ib/II study combining ibrutinib with Glaxo's Arzerra in patients with relapsed/refractory CLL. The overall response rate to the combination therapy was 100%, all partial responses.
Founded in 1999, the company's first marketed antibody, ofatumumab (Arzerra®), was approved to treat chronic lymphocytic leukemia in patients who are refractory to fludarabine and alemtuzumab after less than eight years in development. Genmab's ...